VanEck Vectors Biotech ETF (NASDAQ:BBH)

The Best Biotech ETFs to Buy Ahead of ASCO

The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference ...
Read Full Story »

Why 6 Top Biotech Stocks Could Beat Wall Street Q4 Estimates

If most investors thought their portfolios took a beating during the final quarter of 2018, it was a good thing they were not all-in on the biotechnology segment. The VanEck ...
Read Full Story »
Stock Split Image

After the Run-Up and Sell-Off, Are Biotechs in a Bubble Against Big Pharma Valuations?

Biotech stocks come and go as far as the flavor of the day for investors. While many of these companies are risky, and while many are too risky for many ...
Read Full Story »
biotech

Daily ETF Folly: Why There Is No True Biotech Representation in ETFs

24/7 Wall St. is taking a daily aim at the world exchange-traded funds (ETFs). Many are great, and many are actively traded and truly represent what investors are trying to ...
Read Full Story »
biotech

ETF Folly: Biotech ETFs, Nothing but Confusion

24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the sector performed ...
Read Full Story »

NASDAQ Changes Up Biotech Index Members & Weightings

Index changes are generally speaking a fairly routine event.  They can also create underlying moves in the companies added and deleted from them as money management firms often buy and ...
Read Full Story »

Measuring Pre-Earnings Upside in Biotechs (DNDN, HGSI, GILD, AMLN, ARIA, INCY, IBB, XBI, BBH)

We have compiled a detailed list of expected upside in the biotech sector.  The sector has consolidated and now there is about to be a rush of earnings reports from ...
Read Full Story »

ETF Watch: Biotechs Fighting M&A Shrinkage (BBH, AMGN, GILD, BIIB, XBI, FBT, CRA, CEPH, IBB)

Biotech is becoming the ever-shrinking stock sector.  It is almost weekly now that a new biotech acquisition is announced.  Big Pharma in the United States and large drugmakers internationally are all interested in ...
Read Full Story »

IPO Watch: The Alternative Genzyme IPO (SNY, GENZ, GCVRZ, BBH, IBB, FBT)

The proposed buyout of Genzyme Corporation (NASDAQ: GENZ) by Sanofi-Aventis (NYSE: SNY) should close this week.  We are about to get a new Genzyme security on the market and that ...
Read Full Story »

Top Investment Trends For Futurists (FFD, AFK, EZA, PHO, PIO, PXN, TINY, LIT, BP, PBW, PZD, PBD, REMX, NLR, MOO, GLD, BBH, IBB, FPX, IPOSX)

Futurists are an odd lot.  Generally, they are authors, scientists,  consultants and economists.  What many people don't know is that investors follow this philosophy as well.  Their goal is to ...
Read Full Story »

Stock Gains Skipping Biotech (GENZ, CELG, GILD, AMGN, BIIB, ALXN, MNKD, HGSI, VVUS, DNDN, BBH, XBI, QQQQ)

Biotech and emerging pharma both seem to have almost no friends today despite a large stock market rally.  It may take a resolution of the Genzyme Corporation (NASDAQ: GENZ) merger, ...
Read Full Story »

BioHealth Business Daily (AGEN, ARRY, GENZ, GILD, HGSI, NPSP, QLTI, RPTP, STEM, BBH, IBB, PBE)

Today's version of the BioHealth Business Daily is rather different as we have a big disappointment from one of the top biotech operations in the world.  BioHealth stocks moving on ...
Read Full Story »

Biotech & BioHealth Business Daily (PFE, MRK, BAX, BDSI, SPPI, GNBT, AVII, CEGE, BBH, GILD, LLY, SNY, BMY, OSIP)

Here are some of today's top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com: New short-interest data suggest traders ...
Read Full Story »

Biotech Movers & Shakers (AMGN, CRME, DNDN, GNVC, DNA, QLTI, TBRN, BBH, XBI)

Biotech’s are sliding along with all the others today. A look at the highlights and outliers:Amgen (NASDAQ: AMGN) and Wyeth (NYSE: WYE) announced that arthritis and psoriasis drug Enbrel will ...
Read Full Story »

Can Genentech Buck Its Long-Term Slide? (DNA, BIIB, NVS, OSIP, AMGN, BBH)

Genentech (NYSE: DNA) is set to report earnings after the close today.  First Call has estimates pegged at $0.67 EPS on revenues of $2.97 Billion.  This will also mark the ...
Read Full Story »